相关实验视频

Updated: Jun 27, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

抑制SRC-3作为侵略性地幔细胞淋巴瘤的潜在治疗策略

Imani Bijou¹, Yang Liu², Dong Lu¹

¹Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas, United States of America.

|April 29, 2024

概括

新型SRC-3抑制剂,SI-10和SI-12,对地幔细胞淋巴瘤 (MCL) 有希望. 在临床前模型中,SI-10的有效性得到了证明,为治疗这种侵袭性B细胞淋巴瘤提供了潜在的新策略.

科学领域:

在瘤学瘤学.
血液学血液学血液学
分子生物学分子生物学

背景情况:

膜细胞淋巴瘤 (MCL) 预后不好,复发频繁,因此需要创新疗法.
SRC-3与B细胞淋巴瘤的进展有关,在患者的淋巴结中观察到高表达.
抑制SRC-3已在其他B细胞淋巴瘤中显示出有效性.

研究的目的:

研究新型SRC-3抑制剂SI-10和SI-12在地幔细胞淋巴瘤中的疗效.
在MCL的临床前模型中评估SI-10的抗淋巴瘤活性.

主要方法:

在实验室中对SI-10和SI-12对MCL细胞系进行细胞毒性测定.
在体内SI-10的有效性研究在免疫能力良好的A20传播小鼠模型和人类PDX模型的MCL.
评估SI-10对抗伊布鲁丁尼布耐药模型中生存和毒性的影响.

主要成果:

在实验室中,SI-10和SI-12对一组MCL细胞系表现出剂量依赖的细胞毒性.
在两种不同的IBRUTINIB耐药B细胞淋巴瘤和MCL模型中,SI-10在体内证明了疗效.
在这些临床前模型中,SI-10治疗显著延长了低毒性生存期.

结论:

SI-10通过抑制SRC-3活性而作为一种新型抗淋巴瘤化合物.
准SRC-3值得进一步研究,因为它是改善淋巴瘤治疗结果的联合策略.
这些发现表明,地板细胞淋巴瘤的潜在新治疗途径,特别是在耐药病例中.

更多相关视频

Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy

Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy

Published on: September 16, 2019

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...